CLINICAL_TRIALS ClinicalTrials.gov record update

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Versus Standard Treatment for Medium-risk HER2-positive Early Breast Cancer: a Randomized, Multi-center Trial (EXTEND)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06548178
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:17.645419+00:00
Published At: 2024-08-12T00:00:00+00:00
Record Updated At: 2024-08-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HER2-positive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-12"
protocolSection.identificationModule.nctId: "NCT06548178"
protocolSection.identificationModule.officialTitle: "Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Versus Standard Treatment for Medium-risk HER2-positive Early Breast Cancer: a Randomized, Multi-center Trial (EXTEND)"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.